2019
Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratio
2016
Expression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original Research
2013
Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells
Katz SG, LaBelle JL, Meng H, Valeriano RP, Fisher JK, Sun H, Rodig SJ, Kleinstein SH, Walensky LD. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells. Blood 2013, 123: 884-893. PMID: 24352880, PMCID: PMC3916879, DOI: 10.1182/blood-2013-04-499079.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCyclin D1 transgenic miceCyclin D1 overexpressionB cellsCell lymphomaAggressive B-cell lymphomasSubset of miceTransgenic mouse modelB-cell lymphomaDeletion of BimPathogenesis of MCLHuman mantle cell lymphomaDevelopment of MCLStimulation regimensConventional chemotherapyMouse modelLymphoid maturationTransgenic miceLymphomaBIM deletionSelective expansionMiceProapoptotic BimPathogenesisGenetic aberrations